Literature DB >> 17192562

Neurosteroids as endogenous inhibitors of neuronal cell apoptosis in aging.

Ioannis Charalampopoulos1, Vassiliki-Ismini Alexaki, Christos Tsatsanis, Vassilis Minas, Erene Dermitzaki, Iakovos Lasaridis, Lina Vardouli, Christos Stournaras, Andrew N Margioris, Elias Castanas, Achille Gravanis.   

Abstract

The neuroactive steroids dehydroepiandrosterone (DHEA), its sulfate ester DHEAS, and allopregnanolone (Allo) are produced in the adrenals and the brain. Their production rate and levels in serum, brain, and adrenals decrease gradually with advancing age. The decline of their levels was associated with age-related neuronal dysfunction and degeneration, most probably because these steroids protect central nervous system (CNS) neurons against noxious agents. Indeed, DHEA(S) protects rat hippocampal neurons against NMDA-induced excitotoxicity, whereas Allo ameliorates NMDA-induced excitotoxicity in human neurons. These steroids exert also a protective role on the sympathetic nervous system. Indeed, DHEA, DHEAS, and Allo protect chromaffin cells and the sympathoadrenal PC12 cells (an established model for the study of neuronal cell apoptosis and survival) against serum deprivation-induced apoptosis. Their effects are time- and dose-dependent with EC(50) 1.8, 1.1, and 1.5 nM, respectively. The prosurvival effect of DHEA(S) appears to be NMDA-, GABA(A)- sigma1-, or estrogen receptor-independent, and is mediated by G-protein-coupled-specific membrane binding sites. It involves the antiapoptotic Bcl-2 proteins, and the activation of prosurvival transcription factors CREB and NF-kappaB, upstream effectors of the antiapoptotic Bcl-2 protein expression, as well as prosurvival kinase PKCalpha/beta, a posttranslational activator of Bcl-2. Furthermore, they directly stimulate biosynthesis and release of neuroprotective catecholamines, exerting a direct transcriptional effect on tyrosine hydroxylase, and regulating actin depolymerization and submembrane actin filament disassembly, a fast-response cellular system regulating trafficking of catecholamine vesicles. These findings suggest that neurosteroids may act as endogenous neuroprotective factors. The decline of neurosteroid levels during aging may leave the brain unprotected against neurotoxic challenges.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192562     DOI: 10.1196/annals.1366.003

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  28 in total

1.  Expression of Trk A and Src and their interaction with ERβ ligand binding domain show age and sex dependent alteration in mouse brain.

Authors:  M K Thakur; V Paramanik
Journal:  Neurochem Res       Date:  2011-10-20       Impact factor: 3.996

Review 2.  Control of Cell Survival in Adult Mammalian Neurogenesis.

Authors:  H Georg Kuhn
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-10-28       Impact factor: 10.005

3.  Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.

Authors:  Jennifer C Naylor; Jason D Kilts; Christine M Hulette; David C Steffens; Dan G Blazer; John F Ervin; Jennifer L Strauss; Trina B Allen; Mark W Massing; Victoria M Payne; Nagy A Youssef; Lawrence J Shampine; Christine E Marx
Journal:  Biochim Biophys Acta       Date:  2010-05-19

Review 4.  Chromaffin cells as a model to evaluate mechanisms of cell death and neuroprotective compounds.

Authors:  Cristobal de Los Rios; Maria F Cano-Abad; Mercedes Villarroya; Manuela G López
Journal:  Pflugers Arch       Date:  2017-08-19       Impact factor: 3.657

5.  Age-related decline in oligodendrogenesis retards white matter repair in mice.

Authors:  Nobukazu Miyamoto; Loc-Duyen D Pham; Kazuhide Hayakawa; Toshinori Matsuzaki; Ji Hae Seo; Caroline Magnain; Cenk Ayata; Kyu-Won Kim; David Boas; Eng H Lo; Ken Arai
Journal:  Stroke       Date:  2013-07-23       Impact factor: 7.914

6.  Kinetic and structural determinants for GABA-A receptor potentiation by neuroactive steroids.

Authors:  Gustav Akk; Douglas F Covey; Alex S Evers; Steven Mennerick; Charles F Zorumski; Joe Henry Steinbach
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

Review 7.  Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials.

Authors:  Michael S Ritsner
Journal:  CNS Neurosci Ther       Date:  2010       Impact factor: 5.243

8.  Interaction of androsterone and progesterone with inhibitory ligand-gated ion channels: a patch clamp study.

Authors:  Elke Ziegler; M Bodusch; Y Song; K Jahn; H Wolfes; S Steinlechner; R Dengler; J Bufler; K Krampfl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-25       Impact factor: 3.000

Review 9.  Sex, sex steroids, and brain injury.

Authors:  Paco S Herson; Ines P Koerner; Patricia D Hurn
Journal:  Semin Reprod Med       Date:  2009-04-28       Impact factor: 1.303

10.  Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.

Authors:  Christine E Marx; Jimmy Lee; Mythily Subramaniam; Attilio Rapisarda; Dianne C T Bautista; Edwin Chan; Jason D Kilts; Robert W Buchanan; Eu Pui Wai; Swapna Verma; Kang Sim; Jayaraman Hariram; Rajesh Jacob; Richard S E Keefe; Siow Ann Chong
Journal:  Psychopharmacology (Berl)       Date:  2014-07-17       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.